1 / 69

Hem Onc

Hem Onc. Anemia Acquired Bleeding Disorders Transfusion Therapy. Anemia. Category of Causes Analyzing Indices Approach & Treatment. Biggest Takeaway. Anemia is a sign , not a diagnosis. Category of Causes. 1) Blood Loss 2) Decrease RBC Production

eleanorl
Download Presentation

Hem Onc

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Hem Onc Anemia Acquired Bleeding Disorders Transfusion Therapy

  2. Anemia • Category of Causes • Analyzing Indices • Approach & Treatment

  3. Biggest Takeaway Anemia is a sign, not a diagnosis

  4. Category of Causes • 1) Blood Loss • 2) Decrease RBC Production • 3) Increased RBC Destruction*more than one can occur in one person

  5. Category of Causes • 1) Blood Loss - Principles of Hemorrhage Management • 2) Decrease RBC Production • 3) Increased RBC Destruction*more than one can occur in one person

  6. Principles of Hemorrhage Management • Volume Resuscitation • Balanced, minimal crystalloids • Permissive Hypotension • Source Control • GI (Upper, Lower) • Ob/GYN (Ectopic, Abruption, Post-Partum, Non-Pregnancy) • ICH • AAA • Hemoptysis • Nasal • GU/Retroperitoneal • Trauma (Bones/Compartments, Peritoneal, Hemothorax) • Adjuncts • Reverse Coagulopathy • Lethal Triad

  7. Category of Causes • 1) Blood Loss - Principles of Hemorrhage Management • 2) Decrease RBC Production- Nutritional deficiency (iron, folate, B12) - Aplastic or myelodysplastic • 3) Increased RBC Destruction*more than one can occur in one person

  8. Category of Causes • 1) Blood Loss - Principles of Hemorrhage Management • 2) Decrease RBC Production - Nutritional deficiency (iron, folate, B12) - Aplastic or myelodysplastic • 3) Increased RBC Destruction - Sickle-Cell Disease - Drug-induced autoimmune Hemolytic Anemia*more than one can occur in one person

  9. Anemia Indices • MCV • RDW • Ferritin • Reticulocyte Count • Peripheral Blood Smear • Direct/Indirect Coombs Test

  10. Category of Causes • 1) Blood Loss - Principles of Hemorrhage Management • 2) Decrease RBC Production - Nutritional deficiency (iron, folate, B12) - Aplastic or myelodysplastic • 3) Increased RBC Destruction - Sickle-Cell Disease - Drug-induced autoimmune Hemolytic Anemia • Hemodilutional*more than one can occur in one person

  11. Approach & Management • Assess for acute blood loss • Transfuse those who are: - Symptomatic - Hemodynamically unstable - Evidence of tissue hypoxia - Limited cardiopulmonary reserve Liberal transfusion not recommended • Replace nutritional deficits

  12. Acquired Bleeding Disorders • Platelet Defects • Coagulation Disorders

  13. Biggest Takeaway Always consider bleeding disorders when managing hemorrhagic shock/bleeding catastrophes

  14. Acquired Bleeding Disorders • Platelet Defects • Thrombocytopenia - ITP - Drug-Induced - Nonimmune • Functional Platelet Disorders • Coagulation Disorders

  15. Thrombocytopenia • Production • Destruction • Loss • Splenic sequestration

  16. ITP • Antiplatelet antibodies that attack surface glycoproteins (glycoprotein Iib/Iia) leading to platelet destruction, some impaired production • Idiopathic/Primary or Secondary to medical condition (AI, infections) & Drugs • Primary: at any age, typically more female ages 30-60, typically resolves <6mo (viral #1) • Treatment: typically not needed in asymptomatic patients until <30k (supportive care) - Prednisone 1mg/kg/d for 4 weeks; IVIG 1g/kg/d; Rhogam; Monoclonal Abs - Life-threatening: IV Steroids (Dexamethasone) & IVIG, Platelets 2-3x nl, emergent splenectomy

  17. Drug Induced Thrombocytopenia • Presentation similar to ITP • Typically 5-14d after initiation of drug (sooner if re-exposure) • Chronic alcohol use is a common cause • Typically normalizes after cessation of causative agent • Heparin-induced Thrombocytopenia: paradoxical hypercoagulable platelet activation

  18. Nonimmune (Non-Drug) Thrombocytopenia • TTP • HUS • Heparin-Induced Thrombocytopenia (HIT) • DIC • Viral • HELLP/Pre-Eclampsia/Gestational Thrombocytopenia • Liver disease +/- Chronic Alcohol • Excessive Hemorrhage • Hemodialysis, extracorporeal circulation • Splenic sequestration (SCD, Cirrhosis)

  19. Functional Platelet Disorders

  20. Functional Platelet Disorders • Consider transfusing active bleeding patients who have functional platelet disorders to raise levels >50k • Macroglobulinemia – high viscosity can impair platelet function, may need plasmapheresis to reduce protein level to correct hemostatic function

  21. Acquired Bleeding Disorders • Platelet Defects • Thrombocytopenia - ITP - Drug-Induced - Nonimmune • Functional Platelet Disorders • Coagulation Disorders • Liver Disease • Renal Disease • DIC

  22. Liver Disease Coagulopathy • Hepatocytes synthesize all coagulation factors and regulatory proteins (except factor VIII and vWF) - Diseases affecting hepatic parenchyma can result in decreased synthesis of these factors - Includes Vit K dependent factors (also affected by malabsorption, cholestasis, etc.) - PT prolongation common for decompensated hepatic function (poor predictor of bleeding severity) • Concomitant decrease in anticoagulant proteins >> at risk of both bleeding and thrombosis- Twice as likely to develop unprovoked DVT! Higher incidence portal vein thrombosis • Treatment: balanced transfusion as normal, however caution plasma (can precipitate thrombosis, worsen portal hypertension/severity of variceal bleeding); F7 and PCC not shown beneficial, Vit K?

  23. Renal Disease Coagulopathy • Early renal disease: tendency for thrombosis relating to increased production of procoagulant factors, decreased tissue plasminogen activator • Advanced renal disease: platelet dysfunction, decreased ability to adhere to damaged endothelium and aggregate; uremic toxins and impaired drug elimination • Risk for minor (mucosal, cutaneous) and major bleed (ICH, GI) • PT, PTT, platelet numbers normal, bleeding time prolonged • Treatment:Desmopressin (DDAVP) 0.3 mg/kg IV/SC for uremic platelet dysfunction, increases serum vWF and enhances platelet aggregation ; Cryoprecipitate, Conjugated Estrogen, Erythropoiten; Hemodialysis; platelets not helpful (quickly defective)

  24. DIC • Inappropriate widespread activation of coagulation system, thrombin generation, small vessel thrombosis, consumption of clotting factors/platelets • Concomitant activation of fibrinolytic system, fibrin clots, subsequent bleeding

  25. Transfusion Therapy • PRBCs • Platelets • Coagulation Factors/Plasma • Complications

More Related